HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rancés Blanco Selected Research

G(M3) Ganglioside

6/2019Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.
1/2015Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
1/2013Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
1/2013Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis.
1/2012Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer.
1/2011Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.
1/2011Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rancés Blanco Research Topics

Disease

10Neoplasms (Cancer)
06/2021 - 01/2011
3Carcinogenesis
11/2021 - 02/2021
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2015 - 01/2012
2Epstein-Barr Virus Infections
11/2021 - 06/2021
2Melanoma (Melanoma, Malignant)
01/2011 - 01/2011
1Infections
08/2021
1Neoplasm Metastasis (Metastasis)
07/2020
1Sarcoma (Soft Tissue Sarcoma)
06/2019
1Necrosis
03/2013
1Carcinoma (Carcinomatosis)
01/2013
1Lung Neoplasms (Lung Cancer)
01/2013
1Lymphatic Metastasis
01/2013
1Lymphoma (Lymphomas)
01/2013
1Breast Neoplasms (Breast Cancer)
01/2011
1Skin Neoplasms (Skin Cancer)
01/2011

Drug/Important Bio-Agent (IBA)

7G(M3) GangliosideIBA
06/2019 - 01/2011
6Biological ProductsIBA
02/2021 - 01/2011
3GangliosidesIBA
03/2013 - 01/2011
2SmokeIBA
11/2021 - 06/2021
2Proteins (Proteins, Gene)FDA Link
02/2021 - 12/2020
2Epidermal Growth Factor (EGF)IBA
01/2015 - 01/2013
2AntigensIBA
03/2013 - 01/2013
2Monoclonal AntibodiesIBA
01/2013 - 01/2011
1CarcinogensIBA
11/2021
1VaccinesIBA
08/2021
1Environmental Pollutants (Pollutants, Environmental)IBA
06/2021
1XenobioticsIBA
06/2021
1Biological FactorsIBA
02/2021
1Oncogene Proteins (Oncogene Protein)IBA
07/2020
1ParaffinIBA
06/2019
1Formaldehyde (Formol)FDA Link
06/2019
1AntibodiesIBA
03/2013
1Complement System Proteins (Complement)IBA
03/2013
1ErbB Receptors (EGF Receptor)IBA
01/2013
1GlycoconjugatesIBA
01/2013
1Immunoglobulin G (IgG)IBA
01/2013
1Heterophile AntigensIBA
01/2013
1N-glycolylneuraminic acidIBA
01/2013

Therapy/Procedure

3Immunotherapy
01/2013 - 01/2011